While bowel function is the butt of many a bad joke, for those who suffer from IBS (irritable bowel syndrome) it is no laughing matter. Lotonex - a new drug from Glaxo-Wellcome - promises relief to the 20% of adults who are estimated to suffer from this painful and often stress-related condition. Unlike existing treatments, the active ingredient (called Alosetron) acts directly on serotonin receptor sites in the nervous system. This reduces the sensitivity of the gut, alleviating the chronic abdominal pain and diarrhoea which characterise many cases of IBS. What's more, the drug has few side effects, though it can cause constipation. Lotonex is currently undergoing advance clinical trials in the US and should be available there next year, but European approval is unlikely to be granted before 2001. When it does arrive, however, sales are predicted to be brisk.
ONE MINUTE BRIEFING: Funding XChange's Katrin Herrling channels her inner mentors when making tough calls.
FROM THE ARCHIVE: You may be in charge, but are you really the model leader that you see in your mind's eye? Here are the telltale signs that your management style needs a makeover.
ONE MINUTE BRIEFING: Rod Aldridge, founder and former CEO of Capita, explains his rules for working with the public sector.
ONE MINUTE BRIEFING: CEO Nicholas Anderson on the essence of FTSE 250 engineering firm Spirax Sarco's M&A strategy.
ONE MINUTE BRIEFING: Julian Richer's thriving hi-fi empire is proof that ethical business pays dividends.
FROM THE ARCHIVE: Big data is so yesterday, says Ryan Smith of billion-dollar data firm Qualtrics.